Catalyst Event
Jiangsu Hengrui Pharmaceuticals Co Ltd (1276) · Earnings Release
From Akros SCHK HK-US Biotech Index (ASHUBIO)
3/25/2026, 12:00:00 AM
Announced strong full-year 2025 financial results on March 25, 2026. Revenue grew 13.02% YoY to RMB 31.63 billion, and net profit attributable to shareholders increased 21.69% YoY to RMB 7.71 billion, driven by a 26.09% increase in innovative drug sales.
Korean Translation
2026년 3월 25일, 2025년 연간 실적 발표. 매출은 전년 대비 13.02% 증가한 316.3억 위안, 주주 귀속 순이익은 21.69% 증가한 77.1억 위안을 기록했으며, 이는 혁신 의약품 매출이 26.09% 증가한 데에 기인함.
Related Recent Events
CSPC Pharmaceutical Group Ltd (1093) · Other
Final dividend of HKD 0.15 per share for FY2025 (total HKD 0.29, +11.5% YoY) with ex-dividend date June 24, 2026; low importance as dividend increases typically result in minor positive price adjustments scheduled.
6/24/2026, 12:00:00 AM
Pfizer Inc (PFE) · Earnings Release
High importance is estimated due to the potential for significant price volatility for Pfizer's Q1 2026 earnings release and conference call, scheduled.
5/5/2026, 12:00:00 AM
Eli Lilly and Co (LLY) · Earnings Release
Q1 2026 earnings release and conference call scheduled; typically results in moderate price movement.
4/30/2026, 12:00:00 AM
Bristol-Myers Squibb Co (BMY) · Earnings Release
Q1 2026 earnings release and conference call scheduled.
4/30/2026, 12:00:00 AM
Merck and Co Inc (MRK) · Earnings Release
Q1 2026 earnings release and conference call for 2026-04-30, estimated to have a low impact of ~1-2% based on historical trends, scheduled.
4/30/2026, 12:00:00 AM
Regeneron Pharmaceuticals Inc (REGN) · Earnings Release
Regeneron is scheduled to report its first quarter 2026 financial and operating results on 2026-04-29. Importance is Medium as earnings typically drive significant price movement, scheduled.
4/29/2026, 12:00:00 AM